Photo from wikipedia
Diabetes mellitus‐induced erectile dysfunction (DMED) is one of the complications of diabetes and has a poor response to phosphodiesterase type 5 inhibitor, the first‐line treatment for ED. Saxagliptin (Sax), a… Click to show full abstract
Diabetes mellitus‐induced erectile dysfunction (DMED) is one of the complications of diabetes and has a poor response to phosphodiesterase type 5 inhibitor, the first‐line treatment for ED. Saxagliptin (Sax), a dipeptidyl peptidase‐4 inhibitor (DPP‐4i), has been officially used in the treatment of type 2 diabetes. Stromal cell‐derived factor‐1 (SDF‐1) is one of the important substrates of DPP‐4, and has been proven to be beneficial for several DM complications. However, it is unknown whether Sax contributes to the management of DMED.
Journal Title: Andrology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!